» Articles » PMID: 28181815

Onsite Versus Offsite Radiation Treatment of Malignant Spinal Cord Compression: Lessons from a Safety Net Health System

Overview
Journal Br J Radiol
Specialty Radiology
Date 2017 Feb 10
PMID 28181815
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Metastatic spinal cord compression (MSCC) is an oncologic emergency that often warrants emergent treatment; but, it is unclear whether radiation treatment (RT) can be optimally managed from an offsite radiotherapy facility.

Methods: Patient charts from consecutive patients with MSCC who were treated with radiotherapy alone at either an onsite hospital radiation department (from 2008 to 2012) or an offsite radiotherapy centre (2012-2015) were reviewed. Patient clinical parameters were compared across groups with either the χ test or Fisher's exact test, while survival curves were compared with the log-rank test. The primary end points were ambulatory rate over time, overall survival and cancer-specific survival.

Results: A total of 45 patients were identified, with 19 patients treated onsite in the hospital department and 26 patients treated at the offsite radiotherapy centre with median follow-up of 42 days vs 48.5 days, respectively. The ambulatory rate over time, overall survival and cancer-specific survival were not significantly different between the two eras. Patients treated in-hospital were more likely to start treatment the same day as the consult ("sim and treat") (79% vs 27%, p = 0.006) and were more likely to not complete treatment (26% vs 4%, p = 0.029) as compared with those treated in the offsite centre.

Conclusion: Patients with MSCC can be feasibly treated at an offsite radiotherapy centre with outcomes similar to those treated in-hospital. Advances in knowledge: This is the first study in literature to compare outcomes between onsite and offsite RT of MSCC.

References
1.
Vecht C, Haaxma-Reiche H, van Putten W, de Visser M, Vries E, Twijnstra A . Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology. 1989; 39(9):1255-7. DOI: 10.1212/wnl.39.9.1255. View

2.
Graham P, Capp A, Delaney G, Goozee G, Hickey B, Turner S . A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. Clin Oncol (R Coll Radiol). 2006; 18(1):70-6. DOI: 10.1016/j.clon.2005.08.015. View

3.
Koiter E, Poortmans P, Cloin B . Always on a Friday: referral pattern for metastatic spinal cord compression. Radiother Oncol. 2013; 107(2):259-60. DOI: 10.1016/j.radonc.2013.03.004. View

4.
Rades D, Douglas S, Huttenlocher S, Rudat V, Veninga T, Stalpers L . Validation of a score predicting post-treatment ambulatory status after radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2010; 79(5):1503-6. DOI: 10.1016/j.ijrobp.2010.01.024. View

5.
Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen H . Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994; 30A(1):22-7. DOI: 10.1016/s0959-8049(05)80011-5. View